Last 7 days
4.8%
Last 30 days
-0.5%
Last 90 days
-12.6%
Trailing 12 Months
-4.8%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
BGNE | 309.8B | 1.6B | -14.20% | 63.79% | -161.61 | 198.97 | 77.54% | 1.62% |
ABBV | 285.4B | 56.7B | -8.29% | -4.90% | 24.12 | 4.92 | 0.03% | -39.22% |
REGN | 87.6B | 12.4B | -7.87% | 17.32% | 20.2 | 7.2 | -25.07% | -47.28% |
VRTX | 86.0B | 9.2B | -3.63% | 23.60% | 26.37 | 9.33 | 15.86% | 32.99% |
ALNY | 24.1B | 1.0B | -2.92% | 54.32% | -22.59 | 23.19 | 22.88% | -19.27% |
SRPT | 11.7B | 975.7M | -0.22% | 72.44% | -10.45 | 11.95 | 27.41% | -212.78% |
UTHR | 10.1B | 2.0B | -0.54% | -4.82% | 13.95 | 5.12 | 12.05% | 52.86% |
MID-CAP | ||||||||
MDGL | 4.8B | - | -14.71% | 282.83% | -15.1 | 2.5K | - | -27.52% |
RARE | 3.6B | 363.3M | 17.36% | 1.78% | -5.05 | 9.82 | 3.39% | -55.81% |
BPMC | 3.5B | 204.6M | 12.22% | 2.64% | -6.05 | 17.19 | -7.52% | 10.65% |
MRTX | 2.2B | 18.9M | -15.43% | -4.97% | -3.02 | 117.75 | - | -16.17% |
SMALL-CAP | ||||||||
CYTK | 3.7B | - | -1.80% | -6.60% | -8.5 | 38.73 | 34.30% | -67.22% |
CPRX | 1.2B | 256.5M | -30.42% | 62.68% | 12.31 | 4.77 | 66.85% | 120.61% |
MGNX | 300.5M | 165.3M | -29.46% | 47.27% | -3.29 | 1.82 | 130.70% | 57.97% |
CRBP | 41.5M | - | 15.88% | 3252.62% | -0.82 | 19.11 | - | -29.84% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Revenue | 2.3% | 1,981 | 1,936 | 1,860 | 1,789 | 1,768 |
Gross Profit | 3.7% | 1,723 | 1,661 | 1,633 | - | - |
S&GA Expenses | -4.3% | 480 | 501 | - | - | - |
R&D Expenses | 4.3% | 337 | 323 | 312 | 325 | 305 |
Costs and Expenses | 5.1% | 1,005 | 957 | 886 | 900 | 860 |
EBITDA | 4.7% | 1,034 | 988 | 875 | 939 | - |
EBITDA Margin | 0.6% | 0.53* | 0.53* | 0.49* | 0.53* | - |
Earnings Before Taxes | -1.8% | 934 | 951 | 912 | 804 | 870 |
EBT Margin | 0.1% | 0.49* | 0.49* | 0.45* | 0.49* | - |
Interest Expenses | 28.1% | 42.00 | 32.00 | 25.00 | 20.00 | 19.00 |
Net Income | 2.8% | 727 | 707 | 631 | 687 | - |
Net Income Margin | -1.2% | 0.38* | 0.38* | 0.35* | 0.39* | - |
Free Cahsflow | -2.3% | 664 | 679 | 652 | 673 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Assets | 5.0% | 6,346 | 6,045 | 5,782 | 5,543 | 5,360 |
Current Assets | -5.5% | 3,193 | 3,380 | 3,056 | 2,684 | 2,587 |
Cash Equivalents | 21.0% | 1,164 | 961 | 967 | 795 | 813 |
Inventory | 0.5% | 103 | 102 | 91.00 | 90.00 | 88.00 |
Net PPE | 4.1% | 897 | 862 | 841 | 791 | 784 |
Liabilities | -2.0% | 1,223 | 1,248 | 1,219 | 1,225 | 1,184 |
Current Liabilities | -5.4% | 325 | 343 | 316 | 332 | 293 |
Shareholder's Equity | 6.8% | 5,123 | 4,797 | 4,562 | 4,318 | 4,176 |
Retained Earnings | 4.8% | 5,283 | 5,042 | 4,910 | 4,671 | 4,555 |
Additional Paid-In Capital | 2.9% | 2,457 | 2,388 | 2,315 | 2,292 | 2,254 |
Accumulated Depreciation | 3.4% | 377 | 364 | 352 | - | - |
Shares Outstanding | 1.4% | 47.00 | 46.00 | 46.00 | 45.00 | 45.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Cashflow From Operations | 10.7% | 889 | 803 | 849 | 776 | 797 |
Share Based Compensation | 8.1% | 116 | 107 | 87.00 | 114 | 77.00 |
Cashflow From Investing | 17.0% | -673 | -811 | -818 | -959 | -839 |
Cashflow From Financing | 79.0% | 135 | 75.00 | 27.00 | 37.00 | 24.00 |
72.3%
28.1%
12.7%
Y-axis is the maximum loss one would have experienced if United Therapeutics was unfortunately bought at previous high price.
12.8%
9.3%
15.2%
20.8%
FIve years rolling returns for United Therapeutics.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-06-01 | MACQUARIE GROUP LTD | reduced | -21.34 | -12,176,000 | 20,725,000 | 0.03% |
2023-05-30 | Aspire Private Capital, LLC | reduced | -10.34 | -2,242 | 5,823 | -% |
2023-05-26 | ProShare Advisors LLC | reduced | -18.51 | -694,535 | 1,326,070 | -% |
2023-05-23 | BROOKFIELD Corp /ON/ | sold off | -100 | -7,932,520 | - | -% |
2023-05-23 | Seaport Global Advisors, LLC | added | 8.33 | -69,001 | 471,884 | 1.49% |
2023-05-23 | ROYCE & ASSOCIATES LP | unchanged | - | -541,300 | 2,239,600 | 0.02% |
2023-05-23 | Capital Impact Advisors, LLC | sold off | -100 | -277,534 | - | -% |
2023-05-23 | Toroso Investments, LLC | added | 190 | 3,499,000 | 6,108,000 | 0.10% |
2023-05-22 | Raleigh Capital Management Inc. | sold off | -100 | -10,289 | - | -% |
2023-05-22 | EMC Capital Management | unchanged | - | -136,000 | 563,000 | 0.47% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Mar 08, 2023 | blackrock inc. | 10.2% | 4,726,986 | SC 13G/A | |
Feb 14, 2023 | avoro capital advisors llc | 6.3% | 2,865,000 | SC 13G/A | |
Feb 13, 2023 | renaissance technologies llc | 5.14% | 2,344,492 | SC 13G/A | |
Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 9.83% | 4,480,719 | SC 13G/A | |
Feb 06, 2023 | wellington management group llp | 5.64% | 2,569,263 | SC 13G | |
Feb 02, 2023 | rothblatt martine a | 8.0% | 3,919,603 | SC 13G/A | |
Jan 24, 2023 | blackrock inc. | 9.9% | 4,510,211 | SC 13G/A | |
Feb 11, 2022 | renaissance technologies llc | 6.48% | 2,917,191 | SC 13G/A | |
Feb 11, 2022 | avoro capital advisors llc | 6.7% | 3,035,000 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
Jun 01, 2023 | 144 | Notice of Insider Sale Intent | |
Jun 01, 2023 | 4 | Insider Trading | |
May 31, 2023 | SD | SD | |
May 23, 2023 | 4 | Insider Trading | |
May 18, 2023 | 144 | Notice of Insider Sale Intent | |
May 18, 2023 | 4 | Insider Trading | |
May 11, 2023 | 4 | Insider Trading | |
May 08, 2023 | 4 | Insider Trading | |
May 05, 2023 | 144 | Notice of Insider Sale Intent | |
May 04, 2023 | 144 | Notice of Insider Sale Intent |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-06-01 | MAHON PAUL A | sold | -1,254,680 | 209 | -6,000 | evp & general counsel |
2023-06-01 | MAHON PAUL A | acquired | 721,560 | 120 | 6,000 | evp & general counsel |
2023-05-22 | Giltner Richard | acquired | 319,500 | 63.9 | 5,000 | - |
2023-05-22 | Giltner Richard | back to issuer | -1,092,950 | 218 | -5,000 | - |
2023-05-18 | MAHON PAUL A | sold | -1,287,470 | 214 | -6,000 | evp & general counsel |
2023-05-18 | MAHON PAUL A | acquired | 721,560 | 120 | 6,000 | evp & general counsel |
2023-05-10 | PATUSKY CHRISTOPHER | back to issuer | -424,480 | 212 | -2,000 | - |
2023-05-10 | PATUSKY CHRISTOPHER | acquired | 176,060 | 88.03 | 2,000 | - |
2023-05-05 | Mesa Nilda | sold | -80,337 | 214 | -374 | - |
2023-05-04 | MAHON PAUL A | sold | -1,294,900 | 215 | -6,000 | evp & general counsel |
Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions | 3 Months Ended | |
---|---|---|
Mar. 31, 2023 | Mar. 31, 2022 | |
Income Statement [Abstract] | ||
Total revenues | $ 506.9 | $ 461.9 |
Operating expenses: | ||
Cost of sales | 52.3 | 25.9 |
Research and development | 82.9 | 69.0 |
Selling, general, and administrative | 87.3 | 79.0 |
Total operating expenses | 222.5 | 173.9 |
Operating income | 284.4 | 288.0 |
Interest income | 29.2 | 4.3 |
Interest expense | (13.8) | (4.7) |
Other (expense) income, net | (7.9) | 22.8 |
Impairment of investment in privately-held company | 0.0 | (1.7) |
Total other income, net | 7.5 | 20.7 |
Income before income taxes | 291.9 | 308.7 |
Income tax expense | (51.0) | (68.8) |
Net income | $ 240.9 | $ 239.9 |
Net income per common share: | ||
Basic (in dollars per share) | $ 5.20 | $ 5.31 |
Diluted (in dollars per share) | $ 4.86 | $ 5.03 |
Weighted average number of common shares outstanding: | ||
Basic (in shares) | 46.3 | 45.2 |
Diluted (in shares) | 49.6 | 47.7 |
Consolidated Balance Sheets - USD ($) $ in Millions | Mar. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 1,163.5 | $ 961.2 |
Marketable investments | 1,699.9 | 1,877.5 |
Accounts receivable, no allowance for 2023 and 2022 | 134.5 | 220.4 |
Inventories, net | 102.5 | 102.0 |
Other current assets | 92.6 | 219.2 |
Total current assets | 3,193.0 | 3,380.3 |
Marketable investments | 1,765.6 | 1,316.2 |
Goodwill and other intangible assets, net | 44.5 | 44.5 |
Property, plant, and equipment, net | 896.5 | 861.5 |
Deferred tax assets, net | 321.9 | 327.7 |
Other non-current assets | 124.5 | 114.3 |
Total assets | 6,346.0 | 6,044.5 |
Current liabilities: | ||
Accounts payable and accrued expenses | 239.7 | 229.9 |
Share tracking awards plan | 46.3 | 80.8 |
Other current liabilities | 38.6 | 32.5 |
Total current liabilities | 324.6 | 343.2 |
Line of credit | 800.0 | 800.0 |
Other non-current liabilities | 98.2 | 104.6 |
Total liabilities | 1,222.8 | 1,247.8 |
Commitments and contingencies | ||
Stockholders’ equity: | ||
Preferred stock, par value $.01, 10,000,000 shares authorized, no shares issued | 0.0 | 0.0 |
Common stock, par value $.01, 245,000,000 shares authorized, 73,317,754 and 72,651,280 shares issued, and 46,698,538 and 46,032,064 shares outstanding as of March 31, 2023 and December 31, 2022, respectively | 0.7 | 0.7 |
Additional paid-in capital | 2,457.3 | 2,388.4 |
Accumulated other comprehensive loss | (38.8) | (55.5) |
Treasury stock, 26,619,216 shares as of March 31, 2023 and December 31, 2022 | (2,579.2) | (2,579.2) |
Retained earnings | 5,283.2 | 5,042.3 |
Total stockholders’ equity | 5,123.2 | 4,796.7 |
Total liabilities and stockholders’ equity | $ 6,346.0 | $ 6,044.5 |